- Thinly traded micro cap Myovant Sciences (MYOV +17.3%) is up in early trading on increased volume, albeit on turnover of only 63K shares, on the heels of a bullish call from Evercore ISI, who rates the stock a Buy with a $35 (201% upside).
- Two Phase 3 trials, LIBERTY 1 & LIBERTY 2, are assessing lead product candidate relugolix in women with heavy menstrual bleeding associated with uterine fibroids. The primary completion for both studies is December 2018.
- Another Phase 3, HERO, is evaluating relugolix in men with advanced prostate cancer. Its primary completion date is September 2019.
- In June, it launched a Phase 3 program to investigate the use of relugolix in women with endometriosis-related pain. Two Phase 3 studies, SPIRIT 1 and SPIRIT 2, are not yet recruiting patients. The primary completion date for both is December 2019.
- Previously: Myovant sciences initiates Phase 3 clinical program of Relugolix in women with endometriosis-associated pain (June 29)
- Now read: Take Profits On Gilead
Original article